LHC Group, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LHCG research report →
Range $154 – $190
Price Chart
About the company
LHC Group, Inc. is a healthcare organization delivering a comprehensive array of post-acute care services, predominantly serving Medicare recipients across the United States. Its operations are organized into five distinct divisions: Home Health, Hospice, Home and Community-Based Care, Facility-Based Care, and Healthcare Innovations (HCI).
- CEO
- Keith G. Myers
- IPO
- 2005
- Employees
- 29,000
- HQ
- Lafayette, LA, US
Get TickerSpark's AI analysis on LHCG
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $5.29B
- P/E
- 86.20
- PEG
- -1.74
- P/S
- 2.32
- P/B
- 3.26
- EV/EBITDA
- 40.15
- Div Yield
- 0.00%
- Gross Margin
- 38.71%
- Op Margin
- 3.86%
- Net Margin
- 2.64%
- ROE
- 3.81%
- ROIC
- 2.60%
Latest fiscal year · YoY change
- Revenue
- $2.28B+2.8%
- Gross Profit
- $883.61M+0.1%
- Op Income
- $88.14M
- Net Income
- $60.25M-58.0%
- EPS
- $1.97-56.9%
- OCF Growth
- +149.8%
- FCF Growth
- +122.8%
- 52W High
- $169.84
- 52W Low
- $138.57
- 50D MA
- $163.41
- 200D MA
- $163.42
- Beta
- 0.42
- RSI (14)
- 72
- Avg Volume
- 432.02K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
LHC Group said 2022 should be another strong year as demand remains high, labor pressure eases, and the company targets margin expansion and steady cash generation.· February 24, 2022
- 2022 EBITDA margin guidance implies about 11.1%, with management still seeing a long-term 13% to 15% consolidated EBITDA range.
- Operating cash flow was guided to roughly $180 million before CARES Act-related recoupments; after those items and about $20 million of CapEx, management expects about $30 million of residual cash flow before M&A.
- Labor trends improved as quarantine rates fell and hiring remained strong; management said net full-time clinical hiring was about 5% of the base in 2021 and expects more normalization in 2022.
- Hospice showed improving momentum after a leadership realignment, with Q1 pacing to just over 10% organic admission growth and about 18% sequential growth.
- Growth opportunities remain supported by strong referral demand, more non-Medicare episodic business, and targeted M&A in home health and hospice.
The call did not include full quarterly revenue, EPS, or gross margin figures in the transcript. Management said 2022 guidance implies about 11.1% adjusted EBITDA margin, with about $180 million of operating cash flow expected based on roughly 64% conversion from EBITDA to cash. They also said 2021 included about $212 million of Medicare Advance payment recoupments and about $26 million of deferred payroll tax payments, while 2022 has about $106 million of remaining Medicare advances to be recouped and one additional deferred payroll tax payment, leaving roughly $30 million after about $20 million of CapEx before M&A.
Keith Myers framed the quarter around a favorable policy backdrop for home-based care, citing CMS waivers, congressional support for home care and HCBS, and progress on Choose Home. He said demand is not the problem; instead, the near-term challenge has been COVID-related labor disruption, which he views as temporary. His tone was constructive and confident, emphasizing continued organic growth, M&A, and the likelihood that many pandemic-era flexibilities will become more permanent.
Dale Mackel said 2022 guidance implies about 11.1% adjusted EBITDA margin and reiterated a long-term target of 13% to 15% EBITDA margin as COVID fades and M&A is integrated over a 12- to 18-month period. On cash, he guided to roughly $180 million of operating cash flow at about 64% EBITDA-to-cash conversion, then explained that CARES Act recoveries and payroll tax payments reduce that to about $30 million after roughly $20 million of CapEx before M&A. He also said the company exited 2021 at about 2.5x leverage and views 2022 as a pretty benign, basically flat debt year.
Analysts focused on long-term margin potential, cash flow, leverage, labor costs, and the sustainability of growth. Management said contract nursing utilization should fall from about 4% in Q3 to the high-1% to 2% range in the back half of 2022, and that contract labor savings are roughly $1.5 million per quarter for every 100 basis points of improvement. They also addressed concern about a possible 2023 Medicare cut, saying they are pushing back with data and expect to mitigate most proposals, while noting Choose Home is still awaiting a CBO score and depends on legislative vehicles.
The call showed strong demand, with management citing all-time-high referrals and continued growth in non-Medicare episodic admissions and hospice admissions. Labor appears to be improving as quarantine-related shortages ease, which should support higher volume and lower contract labor use. Management also sounded confident that policy trends, including telehealth and home-based care support, are moving in LHC Group’s favor.
The biggest near-term risk remains labor availability and cost, especially in a COVID-disrupted environment with higher wage inflation and reliance on contract labor. Management also flagged ongoing CARES Act recoupments and the possibility of adverse 2023 reimbursement proposals, even though they believe they can mitigate them. The personal care business still has staffing challenges, and management acknowledged supply-chain pressure could push some cost savings into the second half of 2022.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 95.4%
- Shares Outstanding
- 31.15M
- Float Shares
- 29.72M
of shares held by institutions
2 13F filers
Buy/sell ratio 0.32. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for LHCG, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Josh GottheimerHouse · NJ05 | Sell | Jun 21, 22 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | May 9, 22 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Nov 4, 21 | Filing → |
| Sara JacobsHouse · CA53 | Sell | Apr 9, 21 | Filing → |
| Sara JacobsHouse · CA53 | Buy | Feb 19, 21 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Oct 29, 20 | Filing → |
| John YarmuthHouse · KY03 | Sell | Jul 6, 20 | Filing → |
| John YarmuthHouse · KY03 | Sell | Jul 2, 20 | Filing → |
| John YarmuthHouse · KY03 | Sell | Jul 8, 20 | Filing → |
| John YarmuthHouse · KY03 | Sell | Apr 6, 20 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Feb 28, 20 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Mar 3, 20 | Filing → |
| Gilbert CisnerosHouse · CA39 | Buy | Mar 7, 19 | Filing → |
| John YarmuthHouse · KY03 | Sell | Oct 11, 18 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Parametric Portfolio Associates LLC | 100.65K | ▲ 13.45K |
| Spring Creek Capital LLC | 50.00K | ▲ 50.00K |
| Amalgamated Financial Corp. | 21.34K | ▲ 21.34K |
| Sarissa Consulting LLC | 10.00K | ▲ 10.00K |
| Eaton Vance Management | 7.50K | ▲ 230 |
| S. Muoio & Co. LLC | 5.50K | ▲ 2.50K |
| Walthausen & Co., LLC | 5.34K | ▼ 3.40K |
| Advisor Partners LLC | 3.83K | ▲ 312 |
| Regent Investment Management LLC | 1.83K | 0 |
| Private Capital Group, LLC | 652 | ▼ 372 |
| Wipfli Financial Advisors LLC, | 551 | ▲ 551 |
| Fieldpoint Private Securities, LLC | 50 | ▼ 55 |
Held by 7 ETFs
Biggest fund positions in LHCG by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 22, 23 | REED W EARL III | sell | 27,848 |
| Feb 22, 23 | Azare Monica F | sell | 30,500 |
| Feb 22, 23 | Nixon Ronald T | sell | 27,100 |
| Feb 22, 23 | TURNER BRENT | sell | 14,200 |
| Feb 22, 23 | Fontenot Teri G. | sell | 7,700 |
| Feb 22, 23 | Greenstein Bruce D | sell | 30,357 |
| Feb 22, 23 | Greenstein Bruce D | sell | 10,449 |
| Feb 22, 23 | Mackel Dale | sell | 18,039 |
| Feb 22, 23 | GOLDBERG JONATHAN | sell | 16 |
| Feb 22, 23 | Indest John L | sell | 30,576 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our LHCG coverage
Recent articles, reports, and earnings notes.
No research on LHCG yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LHCG report →LHC Group: A Deal That Could Go Through Unchallenged After All
seekingalpha.com · Feb 14
Mergers and Acquisitions in 2023 Off To A Strong Start
marketbeat.com · Jan 27
GDRX or LHCG: Which Is the Better Value Stock Right Now?
zacks.com · Nov 10
LHC Group's (LHCG) Q3 Earnings & Revenues Miss Estimates
zacks.com · Nov 3
LHC Group (LHCG) Q3 Earnings and Revenues Lag Estimates
zacks.com · Nov 2
LHC Group announces third quarter 2022 financial results
prnewswire.com · Nov 2
LHC Group's (LHCG) Latest Tie-Up to Improve Patient Services
zacks.com · Sep 15
LHC Group and University of Maryland Medical System announce home health partnership
prnewswire.com · Sep 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.